Premium
Outcomes following bioprosthetic valve replacement in prior non‐cardiac transplant recipients
Author(s) -
Bozso Sabin J.,
Kang Jimmy J. H.,
AlAdra David,
Hong Yongzhe,
Moon Michael C.,
Freed Darren H.,
Nagendran Jayan,
Nagendran Jeevan
Publication year - 2019
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13720
Subject(s) - medicine , cardiology , intensive care medicine , surgery
Background We report on overall survival and valve‐related outcomes after bioprosthetic valve replacement in prior transplant recipients. Methods From January 2004 to December 2018, 20 consecutive patients (mean age 65.7‐years, 90% male) with prior non‐cardiac transplantation underwent bioprosthetic aortic (n = 18) or combined aortic and mitral (n = 2) valve replacement. Patients consisted of kidney (n = 14), lung (n = 2), liver (n = 3), and bone‐marrow (n = 2) transplants with the most common indication for valve replacement being calcific degeneration (n = 12). Outcomes were measured over a 12‐year span, with a median follow‐up duration of 3.9 years. Results Overall survival at 30 days was 100% and at median follow‐up was 60%. Acute kidney injury occurred in 50% (n = 10) with temporary dialysis required in 5% (n = 1) and 15% (n = 3) suffered respiratory failure. No patients experienced major bleeding, heart failure, or sternal wound infection. No patients required redo valve replacement during the study period. Conclusions Our results provide contemporary data demonstrating that patients with prior transplant can undergo bioprosthetic valve replacement with acceptable inhospital mortality rates and long‐term survival, with a low rate of major morbidity. Furthermore, bioprosthetic valve replacement is a viable option in this group of patients with no redo valve replacement and acceptable long‐term hemodynamic valvular function.